JP7843701B2 - Ｉｌ－３３アンタゴニストの使用方法 - Google Patents

Ｉｌ－３３アンタゴニストの使用方法

Info

Publication number
JP7843701B2
JP7843701B2 JP2022525520A JP2022525520A JP7843701B2 JP 7843701 B2 JP7843701 B2 JP 7843701B2 JP 2022525520 A JP2022525520 A JP 2022525520A JP 2022525520 A JP2022525520 A JP 2022525520A JP 7843701 B2 JP7843701 B2 JP 7843701B2
Authority
JP
Japan
Prior art keywords
abnormal
egfr
antagonist
mucus
rage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500492A (ja
JP2023500492A5 (cg-RX-API-DMAC10.html
Inventor
ダゲール，ラニア
ハウスレイ，カースティ
ゲーディ，マブーベ
ストリクソン，サム
スザンヌ コーエン，エマ
ベルビシ，マリア
ロス，ザビエル ロメロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2023500492A publication Critical patent/JP2023500492A/ja
Publication of JP2023500492A5 publication Critical patent/JP2023500492A5/ja
Priority to JP2025174754A priority Critical patent/JP2026012782A/ja
Application granted granted Critical
Publication of JP7843701B2 publication Critical patent/JP7843701B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022525520A 2019-11-04 2020-11-03 Ｉｌ－３３アンタゴニストの使用方法 Active JP7843701B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025174754A JP2026012782A (ja) 2019-11-04 2025-10-16 Ｉｌ－３３アンタゴニストの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19206984.7 2019-11-04
EP19206984 2019-11-04
PCT/EP2020/080841 WO2021089563A1 (en) 2019-11-04 2020-11-03 Methods of using il-33 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025174754A Division JP2026012782A (ja) 2019-11-04 2025-10-16 Ｉｌ－３３アンタゴニストの使用方法

Publications (3)

Publication Number Publication Date
JP2023500492A JP2023500492A (ja) 2023-01-06
JP2023500492A5 JP2023500492A5 (cg-RX-API-DMAC10.html) 2023-09-27
JP7843701B2 true JP7843701B2 (ja) 2026-04-10

Family

ID=68426347

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525520A Active JP7843701B2 (ja) 2019-11-04 2020-11-03 Ｉｌ－３３アンタゴニストの使用方法
JP2025174754A Pending JP2026012782A (ja) 2019-11-04 2025-10-16 Ｉｌ－３３アンタゴニストの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025174754A Pending JP2026012782A (ja) 2019-11-04 2025-10-16 Ｉｌ－３３アンタゴニストの使用方法

Country Status (10)

Country Link
US (1) US20220380450A1 (cg-RX-API-DMAC10.html)
EP (1) EP4054711A1 (cg-RX-API-DMAC10.html)
JP (2) JP7843701B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220093334A (cg-RX-API-DMAC10.html)
CN (2) CN122140920A (cg-RX-API-DMAC10.html)
AU (2) AU2020379171B2 (cg-RX-API-DMAC10.html)
CA (1) CA3158323A1 (cg-RX-API-DMAC10.html)
IL (1) IL292443A (cg-RX-API-DMAC10.html)
TW (1) TW202134261A (cg-RX-API-DMAC10.html)
WO (1) WO2021089563A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2991847T3 (es) 2021-08-27 2024-12-05 Medimmune Ltd Tratamiento de enfermedad pulmonar obstructiva crónica con un anticuerpo anti-interleucina-33
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
TW202423972A (zh) 2022-08-26 2024-06-16 英商梅迪繆思有限公司 使用抗介白素－３３抗體的氣喘治療

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523089A (ja) 2004-02-17 2007-08-16 シェーリング　コーポレイション インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用
JP2016513644A (ja) 2013-03-13 2016-05-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｉｌ−３３抗体及びその使用
JP2018516853A (ja) 2015-03-31 2018-06-28 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
WO2015032932A1 (en) * 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック， インコーポレイテッド 抗インターロイキン−３３抗体及びその使用
SG11201808693WA (en) 2016-04-27 2018-11-29 Pfizer Anti-il-33 antibodies, compositions, methods and uses thereof
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
WO2018204598A1 (en) 2017-05-03 2018-11-08 The University Of North Carolina At Chapel Hill Methods for diagnosing or predicting chronic bronchitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523089A (ja) 2004-02-17 2007-08-16 シェーリング　コーポレイション インターロイキン−３３（ｉｌ３３）およびｉｌ−３３レセプター複合体の使用
JP2016513644A (ja) 2013-03-13 2016-05-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｉｌ−３３抗体及びその使用
JP2018516853A (ja) 2015-03-31 2018-06-28 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Neuroimmunology, 2012, Vol. 247, pp. 25-31

Also Published As

Publication number Publication date
US20220380450A1 (en) 2022-12-01
AU2020379171B2 (en) 2025-05-08
EP4054711A1 (en) 2022-09-14
AU2020379171A1 (en) 2022-06-09
IL292443A (en) 2022-06-01
JP2026012782A (ja) 2026-01-27
JP2023500492A (ja) 2023-01-06
AU2025213676A1 (en) 2025-08-28
KR20220093334A (ko) 2022-07-05
CA3158323A1 (en) 2021-05-14
CN122140920A (zh) 2026-06-05
WO2021089563A1 (en) 2021-05-14
CN114901361A (zh) 2022-08-12
TW202134261A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
JP7079298B2 (ja) Ｗｎｔ経路関連疾患のための抗体および方法
JP6936784B2 (ja) グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法
JP2026012782A (ja) Ｉｌ－３３アンタゴニストの使用方法
CN103201290B (zh) S100a4抗体及其治疗用途
US20250042986A1 (en) Stem cell factor inhibitor
CA3183867A1 (en) Combination of antibody-drug conjugate and atr inhibitor
WO2020051275A1 (en) Monoclonal antibodies against endotrophin and the use thereof
EA052516B1 (ru) Способы применения антагонистов il-33
US20220363748A1 (en) Anti il-33 therapeutic agent for treating renal disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260331

R150 Certificate of patent or registration of utility model

Ref document number: 7843701

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150